Involvement of tissue plasminogen activator "tPA" in ethanol-induced locomotor sensitization and conditioned-place preference

Behavioural Brain Research

Volumn 226, Issue 1, 2012, Pages 250-258

  Bahi, Amine ^a   Dreyer, Jean Luc ^b  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

Author keywords

Addiction; Alcohol; Behavioral sensitization; CPP; Ethanol; Lentivirus; Plasminogen; ShRNA; TPA

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALCOHOL; ALTEPLASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; LENTIVIRUS VECTOR; RACLOPRIDE; SERINE PROTEINASE; SHORT HAIRPIN RNA; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; ENZYME ACTIVITY; HABITUATION; LOCOMOTION; MALE; MESOLIMBIC DOPAMINERGIC SYSTEM; MICROINJECTION; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL;

ANIMALS; BENZAZEPINES; CONDITIONING, OPERANT; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; MALE; MICE; MICROINJECTIONS; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; RACLOPRIDE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80053602862     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.09.024     Document Type: Article

References (105)

1. Hyman S.E. A man with alcoholism and HIV infection. JAMA 1995, 274:837-843.
2. Weiss F., Lorang M.T., Bloom F.E., Koob G.F. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Pharmacol Exp Ther 1993, 267:250-258.
3. Yoshimoto K., McBride W.J., Lumeng L., Li T.K. Alcohol stimulates the release of dopamine and serotonin in the nucleus accumbens. Alcohol 1992, 9:17-22.
4. Di Chiara G., Imperato A. Ethanol preferentially stimulates dopamine release in the nucleus accumbens of freely moving rats. Eur J Pharmacol 1985, 115:131-132.
5. Di Chiara G., Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1988, 85:5274-5278.
6. Di Chiara G. Alcohol and dopamine. Alcohol Health Res World 1997, 21:108-114.
7. Enoch M.A. The role of GABA(A) receptors in the development of alcoholism. Pharmacol Biochem Behav 2008, 90:95-104.
8. Diana M., Rossetti Z.L., Gessa G. Rewarding and aversive effects of ethanol: interplay of GABA, glutamate and dopamine. Alcohol Alcohol Suppl 1993, 2:315-319.
9. Hodge C.W., Haraguchi M., Chappelle A.M., Samson H.H. Effects of ventral tegmental microinjections of the GABAA agonist muscimol on self-administration of ethanol and sucrose. Pharmacol Biochem Behav 1996, 53:971-977.
10. Ting A.K.R., Dockstader C., Heinmiller A., Grieder T., van der Kooy D. GABA(A) receptors mediate the opposing roles of dopamine and the tegmental pedunculopontine nucleus in the motivational effects of ethanol. Eur J Neurosci 2009, 29:1235-1244.
11. Kemppainen H., Raivio N., Nurmi H., Kiianmaa K. GABA and glutamate overflow in the VTA and ventral pallidum of alcohol-preferring AA and alcohol-avoiding ANA rats after ethanol. Alcohol Alcohol 2010, 45:111-118.
12. Theile J.W., Morikawa H., Gonzales R.A., Morrisett R.A. GABAergic transmission modulates ethanol excitation of ventral tegmental area dopamine neurons. Neuroscience 2010, 172:94-103.
13. Spanagel R., Weiss F. The dopamine hypothesis of reward: past and current status. Trends Neurosci 1999, 22:521-527.
14. Bahi A., Dreyer J.L. Overexpression of plasminogen activators in the nucleus accumbens enhances cocaine-, amphetamine- and morphine-induced reward and behavioral sensitization. Genes Brain Behav 2008, 7:244-256.
15. Melchor J.P., Strickland S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb Haemost 2005, 93:655-660.
16. Bahi A., Kusnecov A., Dreyer J.L. The role of tissue-type plasminogen activator system in amphetamine-induced conditional place preference extinction and reinstatement. Neuropsychopharmacology 2008, 33:2726-2734.
17. Yan Y., Yamada K., Mizoguchi H., Noda Y., Nagai T., Nitta A., et al. Reinforcing effects of morphine are reduced in tissue plasminogen activator-knockout mice. Neuroscience 2007, 146:50-59.
18. Ito M., Nagai T., Mizoguchi H., Fukakusa A., Nakanishi Y., Kamei H., et al. Possible involvement of protease-activated receptor-1 in the regulation of morphine-induced dopamine release and hyperlocomotion by the tissue plasminogen activator-plasmin system. J Neurochem 2007, 101:1392-1399.
19. Nagai T., Kamei H., Ito M., Hashimoto K., Takuma K., Nabeshima T., et al. Modification by the tissue plasminogen activator-plasmin system of morphine-induced dopamine release and hyperlocomotion, but not anti-nociceptive effect in mice. J Neurochem 2005, 93:1272-1279.
20. Yamada K., Nagai T., Nabeshima T. Drug dependence, synaptic plasticity, and tissue plasminogen activator. J Pharmacol Sci 2005, 97:157-161.
21. Nagai T., Noda Y., Ishikawa K., Miyamoto Y., Yoshimura M., Ito M., et al. The role of tissue plasminogen activator in methamphetamine-related reward and sensitization. J Neurochem 2005, 92:660-667.
22. Nagai T., Yamada K., Yoshimura M., Ishikawa K., Miyamoto Y., Hashimoto K., et al. The tissue plasminogen activator-plasmin system participates in the rewarding effect of morphine by regulating dopamine release. Proc Natl Acad Sci USA 2004, 101:3650-3655.
23. Ekici O.D., Paetzel M., Dalbey R.E. Unconventional serine proteases: variations on the catalytic Ser/His/Asp triad configuration. Protein Sci 2008, 17:2023-2037.
24. Page M.J., Di Cera E. Serine peptidases: classification, structure and function. Cell Mol Life Sci 2008, 65:1220-1236.
25. Polgar L. The catalytic triad of serine peptidases. Cell Mol Life Sci 2005, 62:2161-2172.
26. Rymner M.M., Akhtar N., Martin C., Summers D. Management of acute ischemic stroke: time is brain. Mo Med 2011, 107:333-337.
27. Suzuki Y. Role of tissue-type plasminogen activator in ischemic stroke. J Pharmacol Sci 2010, 113:203-207.
28. Zorio E., Gilabert-Estelles J., Espana F., Ramon L.A., Cosin R., Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008, 15:923-929.
29. Teesalu T., Kulla A., Asser T., Koskiniemi M., Vaheri A. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans 2002, 30:183-189.
30. Qian Z., Gilbert M.E., Colicos M.A., Kandel E.R., Kuhl D. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993, 361:453-457.
31. Salles F.J., Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 2002, 22:2125-2134.
32. Pawlak R., Magarinos A.M., Melchor J., McEwen B., Strickland S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat Neurosci 2003, 6:168-174.
33. Zhou Y., Maiya R., Norris E.H., Kreek M.J., Strickland S. Involvement of tissue plasminogen activator in stress responsivity during acute cocaine withdrawal in mice. Stress 2010, 13:481-490.
34. Skrzypiec A.E., Buczko W., Pawlak R. Tissue plasminogen activator in the amygdala: a new role for an old protease. J Physiol Pharmacol 2008, 59(Suppl. 8):135-146.
35. Seeds N.W., Williams B.L., Bickford P.C. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995, 270:1992-1994.
36. Seeds N.W., Basham M.E., Haffke S.P. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci USA 1999, 96:14118-14123.
37. Maiya R., Zhou Y., Norris E.H., Kreek M.J., Strickland S. Tissue plasminogen activator modulates the cellular and behavioral response to cocaine. Proc Natl Acad Sci USA 2009, 106:1983-1988.
38. Nagai T., Nabeshima T., Yamada K. Basic and translational research on proteinase-activated receptors: regulation of nicotine reward by the tissue plasminogen activator (tPA)-plasmin system via proteinase-activated receptor 1. J Pharmacol Sci 2008, 108:408-414.
39. Nagai T., Ito M., Nakamichi N., Mizoguchi H., Kamei H., Fukakusa A., et al. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. J Neurosci 2006, 26:12374-12383.
40. Noel M., Norris E.H., Strickland S. Tissue plasminogen activator is required for the development of fetal alcohol syndrome in mice. Proc Natl Acad Sci USA 2011, 108:5069-5074.
41. Tsirka S.E., Gualandris A., Amaral D.G., Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995, 377:340-344.
42. Tsirka S.E., Rogove A.D., Bugge T.H., Degen J.L., Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997, 17:543-552.
43. Tsirka S.E., Rogove A.D., Strickland S. Neuronal cell death and tPA. Nature 1996, 384:123-124.
44. Sutton R., Keohane M.E., VanderBerg S.R., Gonias S.L. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994, 5:167-171.
45. Melchor J.P., Pawlak R., Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003, 23:8867-8871.
46. Lee J.Y., Kweon H.S., Cho E., Lee J.Y., Byun H.R., Kim D.H., et al. Upregulation of tPA/plasminogen proteolytic system in the periphery of amyloid deposits in the Tg2576 mouse model of Alzheimer's disease. Neurosci Lett 2007, 423:82-87.
47. Medina M.G., Ledesma M.D., Dominguez J.E., Medina M., Zafra D., Alameda F., et al. Tissue plasminogen activator mediates amyloid-induced neurotoxicity via Erk1/2 activation. EMBO J 2005, 24:1706-1716.
48. Demestre M., Howard R.S., Orrell R.W., Pullen A.H. Serine proteases purified from sera of patients with amyotrophic lateral sclerosis (ALS) induce contrasting cytopathology in murine motoneurones to IgG. Neuropathol Appl Neurobiol 2006, 32:141-156.
49. Nagai T., Murai R., Matsui K., Kamei H., Noda Y., Furukawa H., et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 2009, 202:315-328.
50. Qu W.M., Huang Z.L., Xu X.H., Matsumoto N., Urade Y. Dopaminergic D1 and D2 receptors are essential for the arousal effect of modafinil. J Neurosci 2008, 28:8462-8469.
51. Wang J., Angulo J.A. Methamphetamine induces striatal neurokinin-1 receptor endocytosis primarily in somatostatin/NPY/NOS interneurons and the role of dopamine receptors in mice. Synapse 2010, 65:300-308.
52. Bahi A., Boyer F., Bussard G., Dreyer J.L. Silencing dopamine D3-receptors in the nucleus accumbens shell in vivo induces changes in cocaine-induced hyperlocomotion. Eur J Neurosci 2005, 21:3415-3426.
53. Bahi A., Boyer F., Chandrasekar V., Dreyer J.L. Role of accumbens BDNF and TrkB in cocaine-induced psychomotor sensitization, conditioned-place preference, and reinstatement in rats. Psychopharmacology (Berl) 2008, 199:169-182.
54. Bahi A., Boyer F., Gumy C., Kafri T., Dreyer J.L. In vivo gene delivery of urokinase-type plasminogen activator with regulatable lentivirus induces behavioural changes in chronic cocaine administration. Eur J Neurosci 2004, 20:3473-3488.
55. Bahi A., Boyer F., Kafri T., Dreyer J.L. CD81-induced behavioural changes during chronic cocaine administration: in vivo gene delivery with regulatable lentivirus. Eur J Neurosci 2004, 19:1621-1633.
56. Bahi A., Boyer F., Kafri T., Dreyer J.L. Silencing urokinase in the ventral tegmental area in vivo induces changes in cocaine-induced hyperlocomotion. J Neurochem 2006, 98:1619-1631.
57. Bahi A., Boyer F., Kolira M., Dreyer J.L. In vivo gene silencing of CD81 by lentiviral expression of small interference RNAs suppresses cocaine-induced behaviour. J Neurochem 2005, 92:1243-1255.
58. Bahi A., Kusnecov A.W., Dreyer J.L. Effects of urokinase-type plasminogen activator in the acquisition, expression and reinstatement of cocaine-induced conditioned-place preference. Behav Brain Res 2008, 191:17-25.
59. Ortiz O., Delgado-Garcia J.M., Espadas I., Bahi A., Trullas R., Dreyer J.L., et al. Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci 2010, 30:12288-12300.
60. Bahi A., Mineur Y.S., Picciotto M.R. Blockade of protein phosphatase 2B activity in the amygdala increases anxiety- and depression-like behaviors in mice. Biol Psychiatry 2009, 66:1139-1146.
61. Franklin B.J., Paxinos G.T. The Mouse Brain in Stereotaxic Coordinates 1996, Academic Press, New York.
62. Gualandris A., Jones T.E., Strickland S., Tsirka S.E. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J Neurosci 1996, 16:2220-2225.
63. Parmer R.J., Mahata M., Mahata S., Sebald M.T., O'Connor D.T., Miles L.A. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem 1997, 272:1976-1982.
64. Gravanis I., Tsirka S.E. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets 2008, 12:159-170.
65. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 1995, 18:463-495.
66. Gorelick D.A. Alcohol and cocaine. Clinical and pharmacological interactions. Recent Dev Alcohol 1992, 10:37-56.
67. Koob G.F., Weiss F. Neuropharmacology of cocaine and ethanol dependence. Recent Dev Alcohol 1992, 10:201-233.
68. Wise R.A. The role of reward pathways in the development of drug dependence. Pharmacol Ther 1987, 35:227-263.
69. Crabbe J.C., Phillips T.J., Cunningham C.L., Belknap J.K. Genetic determinants of ethanol reinforcement. Ann N Y Acad Sci 1992, 654:302-310.
70. Stewart R.B., Perlanski E., Grupp L.A. Ethanol as a reinforcer for rats: factors of facilitation and constraint. Alcohol Clin Exp Res 1988, 12:599-608.
71. Liu Y., Le Foll B., Liu Y., Wang X., Lu L. Conditioned place preference induced by licit drugs: establishment, extinction, and reinstatement. Scientific World J 2008, 8:1228-1245.
72. Aguilar M.A., Rodriguez-Arias M., Minarro J. Neurobiological mechanisms of the reinstatement of drug-conditioned place preference. Brain Res Rev 2009, 59:253-277.
73. Li T.K., Spanagel R., Colombo G., McBride W.J., Porrino L.J., Suzuki T., et al. Alcohol reinforcement and voluntary ethanol consumption. Alcohol Clin Exp Res 2001, 25:117S-126S.
74. Yang X., Diehl A.M., Wand G.S. Ethanol exposure alters the phosphorylation of cyclic AMP responsive element binding protein and cyclic AMP responsive element binding activity in rat cerebellum. J Pharmacol Exp Ther 1996, 278:338-346.
75. Constantinescu A., Diamond I., Gordon A.S. Ethanol-induced translocation of cAMP-dependent protein kinase to the nucleus. Mechanism and functional consequences. J Biol Chem 1999, 274:26985-26991.
76. Constantinescu A., Gordon A.S., Diamond I. cAMP-dependent protein kinase types I and II differentially regulate cAMP response element-mediated gene expression: implications for neuronal responses to ethanol. J Biol Chem 2002, 277:18810-18816.
77. Asher O., Cunningham T.D., Yao L., Gordon A.S., Diamond I. Ethanol stimulates cAMP-responsive element (CRE)-mediated transcription via CRE-binding protein and cAMP-dependent protein kinase. J Pharmacol Exp Ther 2002, 301:66-70.
78. Choi D.S., Cascini M.G., Mailliard W., Young H., Paredes P., McMahon T., et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci 2004, 7:855-861.
79. Rani C.S., Qiang M., Ticku M.K. Potential role of cAMP response element-binding protein in ethanol-induced N-methyl-d-aspartate receptor 2B subunit gene transcription in fetal mouse cortical cells. Mol Pharmacol 2005, 67:2126-2136.
80. Shen E.H., Crabbe J.C., Phillips T.J. Dopamine antagonist effects on locomotor activity in naive and ethanol-treated FAST and SLOW selected lines of mice. Psychopharmacology (Berl) 1995, 118:28-36.
81. Hodge C.W., Samson H.H., Chappelle A.M. Alcohol self-administration: further examination of the role of dopamine receptors in the nucleus accumbens. Alcohol Clin Exp Res 1997, 21:1083-1091.
82. de Araujo N.P., Fukushiro D.F., Grassl C., Hipolide D.C., Souza-Formigoni M.L., Tufik S., et al. Ethanol-induced behavioral sensitization is associated with dopamine receptor changes in the mouse olfactory tubercle. Physiol Behav 2009, 96:12-17.
83. Guan X., Tao J., Li S. Dopamine D1 receptor, but not dopamine D2 receptor, is a critical regulator for acute cocaine-enhanced gene expression. Neurol Res 2009, 31:17-22.
84. Shi X., McGinty J.F. D1 and D2 dopamine receptors differentially mediate the activation of phosphoproteins in the striatum of amphetamine-sensitized rats. Psychopharmacology (Berl) 2010.
85. Nijholt I., Blank T., Ahi J., Spiess J. In vivo CREB phosphorylation mediated by dopamine and NMDA receptor activation in mouse hippocampus and caudate nucleus. Brain Res Gene Expr Patterns 2002, 1:101-106.
86. Lee J., Rushlow W.J., Rajakumar N. L-type calcium channel blockade on haloperidol-induced c-Fos expression in the striatum. Neuroscience 2007, 149:602-616.
87. Dreyer J.L. Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Mol Biotechnol 2011, 47:169-187.
88. Dreyer J.L. Lentiviral vector-mediated gene transfer and RNA silencing technology in neuronal dysfunctions. Methods Mol Biol 2010, 614:3-35.
89. Lundberg C., Bjorklund T., Carlsson T., Jakobsson J., Hantraye P., Deglon N., et al. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr Gene Ther 2008, 8:461-473.
90. Farah M.H. RNAi silencing in mouse models of neurodegenerative diseases. Curr Drug Deliv 2007, 4:161-167.
91. Hoyer D. RNA interference for studying the molecular basis of neuropsychiatric disorders. Curr Opin Drug Discov Dev 2007, 10:122-129.
92. Fountaine T.M., Wood M.J., Wade-Martins R. Delivering RNA interference to the mammalian brain. Curr Gene Ther 2005, 5:399-410.
93. Davidson B.L., Paulson H.L. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 2004, 3:145-149.
94. Tirelli E., Laviola G., Adriani W. Ontogenesis of behavioral sensitization and conditioned place preference induced by psychostimulants in laboratory rodents. Neurosci Biobehav Rev 2003, 27:163-178.
95. Sanchis-Segura C., Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict Biol 2006, 11:2-38.
96. Lochner J.E., Honigman L.S., Grant W.F., Gessford S.K., Hansen A.B., Silverman M.A., et al. Activity-dependent release of tissue plasminogen activator from the dendritic spines of hippocampal neurons revealed by live-cell imaging. J Neurobiol 2006, 66:564-577.
97. Pothakos K., Robinson J.K., Gravanis I., Marsteller D.A., Dewey S.L., Tsirka S.E. Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA-/-) mice. Brain Res 2010, 1326:135-142.
98. Pawlak R., Rao B.S., Melchor J.P., Chattarji S., McEwen B., Strickland S. Tissue plasminogen activator and plasminogen mediate stress-induced decline of neuronal and cognitive functions in the mouse hippocampus. Proc Natl Acad Sci USA 2005, 102:18201-18206.
99. Horwood J.M., Ripley T.L., Stephens D.N. DRL performance in mice with deletion of tPA, uPA or PAI-1 genes. Behav Pharmacol 2001, 12:487-496.
100. Centonze D., Saulle E., Pisani A., Bonsi P., Tropepi D., Bernardi G., et al. Tissue plasminogen activator is required for striatal post-ischemic synaptic potentiation. Neuroreport 2002, 13:115-118.
101. Zhou F.C., Anthony B., Dunn K.W., Lindquist W.B., Xu Z.C., Deng P. Chronic alcohol drinking alters neuronal dendritic spines in the brain reward center nucleus accumbens. Brain Res 2007, 1134:148-161.
102. Piechota M., Korostynski M., Solecki W., Gieryk A., Slezak M., Bilecki W., et al. The dissection of transcriptional modules regulated by various drugs of abuse in the mouse striatum. Genome Biol 2010, 11:R48.
103. Hamilton G.F., Whitcher L.T., Klintsova A.Y. Postnatal binge-like alcohol exposure decreases dendritic complexity while increasing the density of mature spines in mPFC Layer II/III pyramidal neurons. Synapse 2010, 64:127-135.
104. Hamilton D.A., Akers K.G., Rice J.P., Johnson T.E., Candelaria-Cook F.T., Maes L.I., et al. Prenatal exposure to moderate levels of ethanol alters social behavior in adult rats: relationship to structural plasticity and immediate early gene expression in frontal cortex. Behav Brain Res 2010, 207:290-304.
105. Carpenter-Hyland E.P., Chandler L.J. Homeostatic plasticity during alcohol exposure promotes enlargement of dendritic spines. Eur J Neurosci 2006, 24:3496-3506.